祐森健恒TYK2别构抑制剂在澳大利亚完成首例受试者给药

【重磅录像】颜宁:“AI在结构生物学中的未达之地”

Usynova Initiates First-in-Human Phase 1 Clinical Trial of Allosteric TYK2 Inhibitor UA021 in Australia
祐森健恒TYK2别构抑制剂在澳大利亚完成首例受试者给药
Usynova Pharmaceuticals Ltd, a private and clinical stage biotechnology company focused on developing innovative medicines for treatment of cancer and inflammatory diseases, today announced the dosing of first healthy volunteer in Australia in a Phase 1 clinical study of UA021, a potent, selective and allosteric investigational tyrosine kinase 2 (TYK2) inhibitor.
“UA021 is an oral small molecule inhibitor that targets the pseudokinase (JH2) domain of TYK2 and has showed superior in vitro and in vivo activities in preclinical studies. The unique PK and superior safety profile of UA021 may provide better in vivo target coverage, and can hopefully translate into differentiated and better efficacy in patients with autoimmune diseases, such as psoriasis and inflammatory bowel disease (IBD). This molecule is ideal for combinational studies for overcoming drug resistance and treatment of hard-to-treat diseases,” commented Shengbin Peng, Ph.D., CSO of Usynova.
“UA021 program is an excellent reflection of our R&D effectiveness. It took us approximately 20 months from project initiation, lead identification and optimization to first human dose. We are committed to develop this important molecule in China and globally, and the Phase I clinical study in China will likely occur in first quarter, 2023,” added Tao Hu, Ph.D., CEO of Usynova.
The first-in-human Phase 1 trial (ACTRN12622001349730) is designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of UA021. The trial is expected to enroll 64 healthy volunteers in Australia, and a separate Phase I study in China is planned in Q1, 2023.

About UA021

UA021 is a potent, selective, and orally bioavailable TYK2 inhibitor. It allosterically targets the pseudokinase (JH2) domain of TYK2 with strong selectivity against other members of JAK family. Thus, it is expected to overcome the toxicities caused by active site JAK inhibitors due to their pan-inhibition of JAK family members. UA021 has showed similar or superior in vitro and in vivo activities to other competitors in preclinical studies, and demonstrated excellent safety profile in preclinical toxicity evaluation. It has the potential to achieve better in vivo target coverage and efficacy in patients. UA021 is currently being evaluated in a Phase 1 clinical study in Australia.

About TYK2

TYK2 is a member of the JAK family including JAK1, JAK2, JAK3 and TYK2. It is a critical component involved in signaling pathways mediated by many pro-inflammatory cytokines such as IL-12, IL-23, and Type 1 interferons. The dysfunction of these cytokines plays a determinant role in the induction of inflammation which is implicated in many immune-mediated disorders such as psoriasis, IBD and other autoimmune diseases.

About Usynova

Usynova Pharmaceuticals Ltd, located at Zhangjiang Hi-Tech Park, Shanghai, is a private and clinical stage biotechnology company focused on developing innovative medicines for treatment of cancer and autoimmune diseases. The company has established internal drug discovery platforms of small molecules and biologics. It currently has multiple pipeline products at different R&D stages. UA007, the lead asset of the company is currently in phase II clinical studies for two indications, gouty arthritis and chemotherapy-induced diarrhea (CID). The early clinical POC results of UA007 in both indications were achieved in the ongoing phase II studies. Gouty arthritis is one of the most common diseases in China and globally, and the current treatments often have drug resistance or undesirable side effects. CID is one of the main side effects of cancer chemotherapy, and it is also an important reason for cancer patients to withdraw from chemotherapy. However, there is currently no effective medicine for treatment of CID. In addition to UA007 and UA021, the company also has a few small molecules in late stage preclinical development.
祐森健恒TYK2别构抑制剂在澳大利亚完成首例受试者给药
祐森健恒TYK2别构抑制剂在澳大利亚完成首例受试者给药
祐森健恒TYK2别构抑制剂在澳大利亚完成首例受试者给药
祐森健恒TYK2别构抑制剂在澳大利亚完成首例受试者给药
祐森健恒生物医药(上海)有限公司(“祐森健恒”)的TYK2别构抑制剂UA021再传捷报,继获得国内临床试验申请受理通知书后,澳大利亚I期临床也进展顺利,于2022年12月19日完成首例健康受试者给药。
祐森健恒TYK2别构抑制剂在澳大利亚完成首例受试者给药
祐森健恒CSO彭生斌博士表示:“UA021此次给药,标志着公司开发的TYK2小分子别构抑制剂治疗银屑病等自身免疫性疾病进入到临床阶段,彰显了公司在该疾病领域中强大的药物研发实力。后续将根据产品的特点和创新的临床开发策略,加速UA021在全球的开发进程”。
祐森健恒CEO胡滔博士强调:“UA021项目顺利且快速在中澳两国同步推进,体现了祐森健恒立足国内、放眼国际的发展决心”。
近期,武田(Tekeda)以60亿美元从Nimbus收购了后者完成II b阶段临床的在研TYK2别构抑制剂NDI-034858。这一消息再度点燃业界对TYK2别构位点的热情。祐森健恒的TYK2别构抑制剂在澳洲的一期临床,是中国创新药有能力进军国际主流市场的例证。需要特别指出的是,祐森健恒的UA021项目从立项、确认PCC到首次人体给药,只用了不到20个月。这充分体现了公司科研团队对项目的深刻理解和高效的组织和执行能力。

关于UA021

UA021是祐森健恒生物医药(上海)有限公司研发的口服小分子TYK2别构抑制剂。临床前研究表明,与同类型其他药品相比,UA021具有更好的药代动力学性质,且在动物毒理实验中表现出很好的安全性,此外, UA021 在临床上有望耐受更高的给药剂量,从而达到更好的治疗效果。这对于需要高剂量给药的IBD、红斑狼疮等疾病的治疗有着重要的意义。

关于TYK2

TYK2是Janus激酶家族(JAK)的成员,参与细胞因子IL-23、IL-12、I型IFN的信号传导,并介导下游的STAT磷酸化,这一通路机制已被证实是银屑病和其他自身免疫病的重要致病机制。目前已批准上市的活性中心JAK抑制剂,由于靶点选择性差,临床应用中易引起血液毒性等严重副作用,被FDA赋予“黑框警告”。UA021通过分子别构机制特异性抑制TYK2,对JAK家族的其他成员有良好的选择, 从而降低因多个JAK 家族成员的抑制而导致的不良反应。其同类药 Deucravacitinib已经在III期临床研究中获得很好的疗效并获得FDA批准上市,国内尚无同类产品上市,UA021有望成为同领域中有差异化和竞争力的药物。

关于祐森建恒

生物医药(上海)有限公司成立于2020年1月。公司聚焦于自身免疫性疾病和癌症两大领域,立足于解决未满足的临床需求,开发具有自主知识产权的一类新药。公司拥有国内一流的管理团队,具备顶尖的研发实力。创始人及核心团队成员来自跨国药企、国内CRO龙头企业,在小分子药物、抗体药物研发领域具有深厚的项目积累,尤其是在肿瘤及免疫领域有多年开发经验。公司研发管线丰富,有10多个主要在研产品,包括First-in-class项目。
祐森健恒TYK2别构抑制剂在澳大利亚完成首例受试者给药点击这里,更多了解祐森健恒!

本篇文章来源于微信公众号:药时代

发布者:永恒,转载请首先联系contact@drugtimes.cn获得授权

(0)
打赏 为好文打赏 支持药时代 共创新未来! 为好文打赏 支持药时代 共创新未来!
上一篇 2022年12月20日 15:28
下一篇 2022年12月20日 15:29

相关推荐

公众号
公众号
分享本页
返回顶部
FDA批准首款NASH/MASH新药,中国药企如何分享这个百亿美元大蛋糕?点击观看直播